On July 14, 2025, Scotiabank initiated coverage on Gossamer Bio (GOSS, Financial), setting a current price target of $11.00 USD. This announcement was made by analyst Greg Harrison, highlighting the firm's positive outlook on the stock.
Gossamer Bio (GOSS, Financial) has been assigned a "Sector Outperform" rating by Scotiabank, indicating strong performance expectations relative to its sector peers. This marks the first time Scotiabank has provided coverage or a rating for GOSS, with no previous price target to compare against.
Investors interested in Gossamer Bio (GOSS, Financial) are advised to take note of this new analyst coverage as it may impact the stock's market performance and investor sentiment.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Gossamer Bio Inc (GOSS, Financial) is $8.60 with a high estimate of $15.00 and a low estimate of $4.00. The average target implies an upside of 532.35% from the current price of $1.36. More detailed estimate data can be found on the Gossamer Bio Inc (GOSS) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Gossamer Bio Inc's (GOSS, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
